In a research in breast cancer cells, the combination of lapatinib, a dual HER2/neu and EGFR tyrosine kinase inhibitor, with INK128 prevented each HER2 and HER3 phosphorylation induced by INK128 and developed synergistic induction of mobile Loss of life in numerous HER2-beneficial mobile traces resistant to trastuzumab and lapatinib. In https://haimo429bfk2.blog-gold.com/profile